2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Clinical Procedures, Treatment Considerations, Combination Therapy, Supportive Care, Biological Therapies, Transplantation, Non-Biological Therapies, Chemotherapy, Radiation Therapy, Adverse Events, Biological Processes, Immune Mechanism, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Patient Safety, Practice Models, Quality Improvement, Diseases, Bleeding and Clotting, Immunology, GVHD, Immunodeficiency, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, ALL, Research, AML, MDS, Clinical Research, Clinical Trials, Health Outcomes Research, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric
PAPER

5987 Comparative outcomes of reduced-intensity conditioning using post-transplant cyclophosphamide-based GVHD prophylaxis in lymphomas: A study on behalf of the EBMT lymphoma working party

Alberto Mussetti, Raffaella Greco2, Maud Ngoya3, Irma Khvedelidze4, Raynier Devillier, PhD5, Stefania Bramanti, MD6, Aitana Balaguer Roselló, MD, PhD7, Enrico Derenzini8, Khalid Halahleh, MD9, Ibrahim Yakoub-Agha10, Inmaculada Concepcion Herrera Arroyo11, Simona Sica12, Yasmina Serroukh13, Pauline Verot14, Montserrat Rovira15, Carlos Solano, MD, PhD16, Virginie Gandemer, MD, PhD17, Patrice Chevallier18, Edouard Forcade, MD, PhD19, Hélène Labussière-Wallet20, Arancha Bermúdez21, Matthew Collin, Professor22, Anna Dodero23, Ben Uttenthal24, Andrew Bruce McDonald25, Gwendolyn Van Gorkom26, Ali Bazarbachi27
1 Intitut Català d'Oncologia - Hospital Duran i Reynals, Barcelona, Spain
2 Ospedale San Raffaele, Milan, Italy
3 EBMT Paris Study Unit, Department of Haematology, Paris, France
4 EBMT Paris Study Unit, Department of Haematology, Paris, France
5 Institut Paoli-Calmettes, Aix Marseille University, Marseille, France
6 IRCCS Humanitas Research Hospital, Milan, Italy
7 Hospital La Fe de Valencia, Valencia, Spain
8 European Institute of Oncology, Milan, Italy
9 King Hussein Cancer Center, Amman, Jordan
10 CHU de Lille, Univ Lille, INSERM U1286, Infinite, Lille, France
11 Hospital Universitario Reina Sofía, Cordoba, Spain
12 Dipartimento di Scienze di Laboratorio ed Ematologiche-Fondazione Policlinico Universitario Agostino Gemelli-IRCCS, Sezione di Ematologia, Dipartimento di Scienze Radiologiche ed Ematologiche, Università Cattolica del Sacro Cuore, Rome, Italy
13 Erasmus MC Cancer Institute, Rotterdam, Netherlands, Rotterdam, Netherlands
14 Hospital Center University De Montpellier, Montpellier, France
15 Stem Cell Transplantation Unit, Hematology Department, Hospital Clínic of Barcelona, Spain, Barcelona, Spain
16 University of Valencia, Valencia, Spain
17 CHU Rennes, Service Onco-hématologie pédiatrique, Rennes, France
18 Nantes University Hospital, Nantes, France, Nantes, France
19 Service d'Hématologie Clinique et Thérapie Cellulaire, CHU Bordeaux, Bordeaux, France
20 Hospital Lyon Sud, Hospices Civils de Lyon, Lyon, France
21 Hospital Universitario Marqués de Valdecilla, Santander, Spain
22 Royal Victoria Infirmary, Newcastle upon Tyne, United Kingdom, Newcastle, United Kingdom
23 Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
24 Department of Haematology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom
25 ABJ Oncology, Pretoria, South Africa
26 Department of Internal Medicine, Division of Hematology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, Netherlands
27 American University of Beirut Medical Center, Beirut, Lebanon

Background: Reduced-intensity conditioning allogeneic hematopoietic cell transplantation (allo-HCT) remains a potentially curative option for patients with relapsed or refractory Hodgkin and non-Hodgkin lymphomas (HL/NHL). To date, no study has directly compared outcomes among the most commonly used RIC/NMA conditioning regimens in patients with HL/NHL uniformly receiving PTCy-based GVHD prophylaxis. 

Methods: We performed a multicenter retrospective study using clinical data from the European Society for Blood and Marrow Transplantation (EBMT) registry. Adult patients (≥18 years) with relapsed/refractory HL/NHL who underwent a first allo-HCT between January 2015 and December 2024 were included. The three most commonly used reduced-intensity conditioning regimens were selected for analysis: fludarabine/cyclophosphamide/TBI (FluCyTBI), thiotepa/busulfan/fludarabine (TBF), and fludarabine/melphalan (FluMel). Matched related, matched unrelated, and haploidentical donors were included. Only patients receiving PTCy-based GVHD prophylaxis were analyzed. 

The primary endpoint was overall survival (OS) from transplantation. Secondary endpoints included progression-free survival (PFS), non-relapse mortality (NRM), relapse/progression (Rel/POD), grade 2–4 acute GVHD, and all-grade chronic GVHD.  

Results: In the HL cohort, 401 patients were included. The median age at transplantation was 33 years (range, 18–72 years); 35% were female, 89% had chemosensitive disease at transplantation, 9% had a Sorror comorbidity index >3, 84% had a Karnofsky performance score >90%, and peripheral blood was the graft source in 74% of cases. Haploidentical donors were the most frequently used donor type (80%), followed by matched unrelated (11%) and matched related donors (9%). Baseline characteristics were similar across the FluCyTBI (n=285), TBF (n=78), and FluMel (n=38) groups. Median follow-up was 3.0 years (range, 2.8–3.6). At 2 years, OS, PFS, NRM, and Rel/POD were 77.4% (95% CI, 72.6–81.5), 64.6% (95% CI, 59.2–69.3), 15.6% (95% CI, 12.0–19.5), and 19.9% (95% CI, 15.8–24.3), respectively. The cumulative incidence of grade 2–4 acute GVHD was 36.1% (95% CI, 31.1–41.0), and that of chronic GVHD was 30.2% (95% CI, 25.3–35.3). In multivariable analysis, FluCyTBI was associated with a lower risk of NRM (HR, 0.40; 95% CI, 0.20–0.80; P=0.01), whereas FluMel was associated with a lower risk of grade 2–4 acute GVHD (HR, 0.33; 95% CI, 0.11–0.96; P=0.04). No significant association between conditioning regimen and the remaining survival outcomes was observed. 

In the NHL cohort, 399 patients were included. diffuse large B-cell lymphoma was the most common subtype (39%), followed by mantle cell lymphoma (22%), peripheral T-cell lymphoma (21%), and follicular lymphoma (18%). The median age at transplantation was 57 years (range, 18–77 years); 36% were female, 87% had chemosensitive disease at transplantation, 18% had a Sorror comorbidity index >3, 74% had a Karnofsky performance score >90%, and peripheral blood was the graft source in 87% of cases. Haploidentical donors were the most frequently used donor type (71%), followed by matched related (15%) and matched unrelated donors (14%). Baseline characteristics were similar across the FluCyTBI (n=221), TBF (n=133), and FluMel (n=45) groups, except for patients receiving FluMel being less likely to have chemosensitive disease at transplantation (73% vs. 86% for TBF vs. 91% for FluCyTBI; P<0.01). Median follow-up was 3.1 years (range, 2.7–3.7). At 2 years, OS, PFS, NRM, and Rel/POD were 58.4% (95% CI, 53.1–63.4), 49.0% (95% CI, 43.7–54.2), 27.4% (95% CI, 23.0–32.1), and 23.5% (95% CI, 19.2–28.1), respectively. The cumulative incidence of grade 2–4 acute GVHD was 32.3% (95% CI, 27.5–37.2), and that of chronic GVHD was 27.2% (95% CI, 22.5–32.1). In multivariable analysis, conditioning regimen was not associated with any survival outcome. 

Conclusions: Among patients with lymphoma undergoing allo-HCT with PTCy-based GVHD prophylaxis, no significant differences in OS, PFS, NRM or relapse/progression were observed among FluCyTBI, TBF, and FluMel conditioning regimens. FluCyTBI was associated with lower NRM only in the HL cohort. Selection of the conditioning regimen should therefore be individualized according to institutional experience and the distinct toxicity profiles of each regimen. 

Alberto Mussetti: SANOFI - Consultancy (Includes expert testimony); AROG - Consultancy (Includes expert testimony); ABBVIE - Consultancy (Includes expert testimony); GEBRO - Consultancy (Includes expert testimony)